Company Overview - Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases [2] - The company is listed on both the Australian Securities Exchange (ASX: IMC) and NASDAQ (NASDAQ: IMRN) [2] Product Information - Travelan® is an orally administered passive immunotherapy that reduces the likelihood of contracting travelers' diarrhea, which is caused by pathogenic bacteria [3] - Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies that binds to diarrhea-causing bacteria, preventing colonization [3] - In Australia, Travelan® is a listed medicine indicated for reducing the risk of travelers' diarrhea and minor gastrointestinal disorders [3] - In Canada, it is a licensed natural health product, while in the U.S., it is sold as a dietary supplement for digestive tract protection [3] Technology and Development - Immuron's proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum, allowing for the production of highly specific immunoglobulins to any enteric pathogen [5] - The platform technology enables the development of medicines across a wide range of infectious diseases, effectively blocking viruses or bacteria at mucosal surfaces [5] Clinical Development - IMM-124E, developed using Immuron's platform technology, targets enterotoxigenic Escherichia coli (ETEC) and is produced from the colostrum of immunized cattle [6][8] - IMM-529 is being developed as an adjunctive therapy for the prevention and treatment of recurrent Clostridioides difficile infection (CDI), targeting key virulence components [9][10] - Pre-clinical results for IMM-529 show promising outcomes in preventing primary disease (80% efficacy), protecting against disease recurrence (67% efficacy), and treating primary disease (78.6% efficacy) [11]
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference